Philips spends big in-house while Becton favours buying
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.
The UK bets on Nanopore and Nudge for rapid Covid-19 tests
Fast tests for Covid-19 infections could be very useful – but only if they are accurate.
Healthineers makes its ambition plain with $16.4bn Varian buy
Suddenly 2020’s medtech M&A landscape looks very different.
US pursues pooled testing for Covid-19, and Quest benefits
Batch testing could allow large numbers of people to be ruled out as having Covid-19, but accuracy concerns remain.
A baptism of fire for listing medtechs
Medtechs going public in 2020 raised a decent amount of cash, but have had a turbulent time of it since.
Medtech venture investors live up to their name
Fortunately for medical device start-ups, it takes more than a pandemic to put venture capitalists off doing deals.
Smaller device makers put in a muted performance
Mid- and small-cap medtechs find themselves at the mercy of government responses to the Covid-19 pandemic.
